VALIGEN ACQUIRES BERLIN-BASED INFOGEN AND PHENOTYPE DATABASE. From: Worldwide Biotech | Date: September 1, 2000 | COPYRIGHT 2000 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group.Copyright information

ValiGen N.V., Newtown, Pa. has acquired Berlin-based INFOGEN Medizinische Genetik GmbH. INFOGEN provides genetic risk assessment and disease management solutions using one of the largest databases of phenotypic profiles and genetic variants, developed to date primarily in the field of cardiovascular disease. Under the terms of the agreement, ValiGen N.V. has acquired all the outstanding common stock of INFOGEN through a share exchange.

"This acquisition represents a bold...

Related newspaper, magazine, and journal articles from HighBeam Research

	Y.F. Leung's Functional Genomics.(txg net) Environmental Health Perspectives ; With its sequencing completed in 2003, scientists set their sights on determining the basic structure and inner workings of the human genome. This movement has spawned numerous new scientific specialties that have been supported by the growth of data-generating technologies. One of these
	Plant Functional Genomics.(BOTANY)(Brief Article)(Book Review) SciTech Book News ; QK981 2004-009819 1-56022-998-5 Plant functional genomics. Title main entry. Ed. by Dario Leister. (Crop science) Food Products Pr., [c]2005 677 p. $129.95 This reference presents a cross-section of current research on the biological function of plant genes and how they work together in health and
	PARADIGM FORMS $55M COLLABORATION WITH MONSANTO. BT Catalyst ; Paradigm Genetics Inc. of Research Triangle Park has signed a broad collaboration agreement with Monsanto Co. (Nyse: MTC) of Madison, N.J., in the field of functional genomics. Under the terms of the agreement, Paradigm will develop functional genomics data by analyzing the product of Monsanto's
	Local VCs missing out on biotech opportunities - expert Jerusalem Post ; SHARON BERGER Jerusalem Post 12-20-2001 Headline: Local VCs missing out on biotech opportunities - expert Byline: SHARON BERGER Edition; Daily Section: Economics Page: 12 Thursday, December 20, 2001 -- Although biopharmaceuticals accounted for an unprecedented 15 percent ($46 million) of total
	The promise of genomics Pharmaceutical Executive ; During the next three years, an estimated $38 billion in brand-name pharmaceuticals will come off patent, leaving a financial void that many pharma companies hope to fill with functional genomics. This relatively new field of genome-wide analysis, which seeks to determine gene function, includes

See all results.